Tolerability of tiagabine: A prospective open-label study

Epileptic Disorders

Volumn 4, Issue 4, 2002, Pages 257-260

  Bauer, Jürgen ^a,e   Bergmann, Arnfin ^b   Reuber, Markus ^a   Stodieck, Stefan Rudolf Günther ^c   Genton, Pierre ^d  

^a UNIVERSITY OF BONN   (Germany)

^b Neurologische Praxis ^*  (Germany)

^c Evangelisches Krankenhaus Alsterdorf   (Germany)

^d CENTRE SAINT PAUL   (France)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Epilepsy; Pharmacotherapy; Tiagabine

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; SUCCINIMIDE DERIVATIVE; TIAGABINE; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUPOR; TREATMENT OUTCOME; TREMOR; VERTIGO;

ADULT; ANTICONVULSANTS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NIPECOTIC ACIDS; PROSPECTIVE STUDIES; STATUS EPILEPTICUS;

EID: 0036925891     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Giardina WJ. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor. J Epilepsy 1994; 7: 161-6.
2. Schachter SC. Tiagabine. Epilepsia 1999; 40 (suppl 5): S17-S22.
3. Commission on Classification and Terminology of the International League against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.
4. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995; 36 (suppl 6): S14-S21.
5. Binnie CB. The efficacy of lamotrigine. Rev Contemp Pharmacotherapy 1994; 5: 115-22.
6. Bauer J, Schwalen S. Topiramate: pharmacological traits and current role in the treatment of epilepsy (in German). Nervenarzt 2000; 71: 495-501.
7. Loiseau P. Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia 1999; 40 (suppl 9): S14-S9.
8. Bauer J, Stawowy B, Lenders T, Bettig U, Elger CE. Efficacy and tolerability of tiagabine: results of an add-on study in patients with refractory partial seizures. J Epilepsy 1995; 8: 83-6.
9. Biraben A, Beaussart M, Josien E, et al. Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study. Epileptic Disord 2001; 3: 91-100.
10. Sommerville KW, Hearell M, Deaton R, Leppik IE. Adverse events with long-term tiagabine therapy. Epilepsia 1997; 38 (suppl 8): 106.
11. Kälviäinen R, Nousiainen, Mantyjarvi IM, Nikoskelainen E, Partanen JPK, Riekinnen PS. Vigabatrin, a gabaergic antiepileptic drug, causes concentric field defects. Neurology 1999; 53: 922-6.
12. Kälviäinen R, Nousiainen I, Mantyjarvi M, Riekkinen P. Absence of concentric visual field defects in patients with long-term tiagabine monotherapy. Neurology 1999; 52 (suppl 2): A236.
13. Shinnar S, Berg AT, Treiman DM, et al. Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons. Epilepsia 2001; 42: 372-9.